WASL and melanoma: Ranking drugs by the number of cell states targeted (Figure 6C, Table S3) revealed several promising but many more unlikely drugs (based on mechanism of action, MOA) targeted the largest number of melanoma states; for example, Ciclacillan [24] (beta-lactam antibiotic), TWS-119 [25] (glycogen kinase 3-beta inhibitor), SB-202190 [26] (p38 MAPK inhibitor), Wiskostatin [27] (N-WASP inhibitor), Ethamivan [28] (respiratory stimulant) and Enalapril [29] (ACE inhibitor).